A lawsuit has been filed on behalf of a Minnesota woman who developed the debilitating and sometimes deadly disease, Nephrogenic Systemic Fibrosis. The woman contracted the disease following an injection of Magnevist Gadolinium contrasting dye manufactured by Bayer-Schering and its subsidiary Berlex Laboratories prior to an MRI (Magnetic Resonance Imaging). Nephrogenic Systemic Fibrosis is the consequence of gadolinium contrasting dye use in those with an impaired renal system such as kidney disease. Those with kidney dysfunction cannot eliminate the toxic dye as quickly and efficiently as those without, causing abhorrent side effects including the thickening and hardening of the skin, joint problems, deep pain in the ribs and hips leaving many wheelchair bound experiencing extreme pain. Death has also been known to occur once the disease reaches the internal organs. The woman received a gadolinium injection in March 2001 and in February 2007 was finally diagnosed with NSF by doctors at the Mayo Foundation. She continues to experience a progressive fibrotic debilitation causing severe impairment. Her lawsuit was filed with the Multidistrict Legislation, Northern District of Ohio alleging that Magnevist is defective and that the creators failed to adequately test and ultimately warn patients about its potential to cause NSF. In September 2007, the Food & Drug Administration (FDA) asked all manufacturers of gadolinium contrast dyes to add a “black box” warning to the product labels about its association with NSF in addition to warning patients with kidney disease who should avoid gadolinium contrast agents. Numerous cases have been filed in many federal districts against gadolinium contrast dye manufacturers. On February 29, 2008 the U.S. Judicial Panel on Multidistrict Litigation designated the U.S. District Court for the Northern District of Ohio as the venue for all the lawsuits that have been filed, and that will be filed in federal district court, against the makers of gadolinium contrast dyes.